Beneficial ownership — 13D / 13G
87,339 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.
Coverage begins December 2024, when the SEC required these schedules to be filed as structured XML.
| Reporting person | Issuer | Schedule | % of class | Event date | Filed |
|---|---|---|---|---|---|
| Ian McDonald | DRUG Bright Minds Biosciences Inc. | 13D/A | 30.56% | Dec 22, 2023 | 2y |
| Erich Spangenberg | MDAI Spectral AI, Inc. | 13D/A | 29.1% | Nov 27, 2023 | 2y |
| Cowen Financial Products LLC | STOK Stoke Therapeutics, Inc. | 13G | 5.77% | Jan 4, 2023 | 2y |
| Landon Lovig | AVNI Arvana Inc | 13G | 5.56% | Jan 3, 2023 | 2y |
| Ian McDonald | DRUG Bright Minds Biosciences Inc. | 13D/A | 8.88% | Dec 1, 2022 | 2y |
| PERCEPTIVE ADVISORS LLC | NVNO enVVeno Medical Corp | 13G/A | 9.9% | Feb 23, 2024 | 2y |
| Point72 Asset Management, L.P. | VTYX Ventyx Biosciences, Inc. Common Stock | 13G | 5.1% | Feb 22, 2024 | 2y |
| Point72 Asset Management, L.P. | CRBU Caribou Biosciences, Inc. | 13G | 5% | Feb 22, 2024 | 2y |
| David A. Ladensohn | SYM Symbotic Inc. | 13D/A | 66% | Feb 21, 2024 | 2y |
| Janet L. Cohen | SYM Symbotic Inc. | 13D/A | 62.6% | Feb 21, 2024 | 2y |
| Abdiel Qualified Master Fund, LP | APPN Appian Corp | 13D/A | 14% | Feb 21, 2024 | 2y |
| Richard B. Cohen | SYM Symbotic Inc. | 13D/A | 68.1% | Feb 21, 2024 | 2y |
| Camac Partners, LLC | ABCP AmBase Corp | 13D/A | 8.7% | Feb 21, 2024 | 2y |
| Kash Sheikh | EVE EVe Mobility Acquisition Corp | 13D/A | 19.2% | Feb 21, 2024 | 2y |
| ADAR1 Partners, LP | TECX Tectonic Therapeutic, Inc. | 13G | 7.4% | Feb 15, 2024 | 2y |
| Deep Track Capital, LP | ENGN enGene Therapeutics Inc. | 13G | 5.21% | Feb 14, 2024 | 2y |
| L1 Capital Global Opportunities Master Fund, Ltd. | SBFM Sunshine Biopharma Inc. | 13G | 5.3% | Feb 13, 2024 | 2y |
| S.H.N. Financial Investments Ltd. | BIOL Biolase, Inc. | 13G | 9.9% | Feb 13, 2024 | 2y |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | BBOT BridgeBio Oncology Therapeutics, Inc. | 13G | 7.4% | Feb 13, 2024 | 2y |
| Yakira Capital Management, Inc. | BITE Bite Acquisition Corp. | 13G/A | 0.75% | Feb 12, 2024 | 2y |
| Brian R. Mariotti | FNKO Funko, Inc. | 13G/A | 1.18% | Dec 31, 2023 | 2y |
| The AES Corporation | FLNC Fluence Energy, Inc. | 13G/A | 29% | Dec 31, 2023 | 2y |
| Hilton Hiller Schlosberg | MNST Monster Beverage Corp | 13D/A | 7.8% | Dec 27, 2023 | 2y |
| EcoR1 Capital, LLC | ZYME Zymeworks Inc. | 13D | 19.99% | Feb 22, 2024 | 2y |
| ASP BB HOLDINGS LLC | BLBD Blue Bird Corp | 13D/A | 0% | Feb 21, 2024 | 2y |
| Bryan G. Glazer Irrevocable Exempt Trust | MANU Manchester United plc | 13D/A | 21.8% | Feb 20, 2024 | 2y |
| VITO GARFI | SQFT Presidio Property Trust, Inc. | 13D/A | 4.1% | Feb 20, 2024 | 2y |
| Kevin Glazer Irrevocable Exempt Family Trust | MANU Manchester United plc | 13D/A | 17.1% | Feb 20, 2024 | 2y |
| Voss Capital, LP | GFF Griffon Corp | 13D/A | 2.6% | Feb 20, 2024 | 2y |
| James N. Topper | KALV KalVista Pharmaceuticals, Inc. | 13D/A | 8.9% | Feb 20, 2024 | 2y |
| Beach Point Capital Management LP | DBD DIEBOLD NIXDORF, Inc | 13D/A | 7.9% | Feb 20, 2024 | 2y |
| Avram Glazer Irrevocable Exempt Trust | MANU Manchester United plc | 13D/A | 18% | Feb 20, 2024 | 2y |
| Darcie S. Glazer Irrevocable Exempt Trust | MANU Manchester United plc | 13D/A | 23.5% | Feb 20, 2024 | 2y |
| First City Investment Group, LLC | MDV Modiv Industrial, Inc. | 13G | 14.7% | Feb 20, 2024 | 2y |
| COWEN AND COMPANY, LLC | CURR Currenc Group Inc. | 13G/A | 8% | Feb 20, 2024 | 2y |
| 180 Degree Capital Corp. | SCOR Comscore, Inc. | 13D/A | 7.2% | Feb 20, 2024 | 2y |
| Joel M. Glazer Irrevocable Exempt Trust | MANU Manchester United plc | 13D/A | 25.7% | Feb 20, 2024 | 2y |
| BIOTECHNOLOGY VALUE FUND L P | ENGN enGene Therapeutics Inc. | 13G/A | 7.2% | Feb 20, 2024 | 2y |
| Group of Trophy, LLC | MDV Modiv Industrial, Inc. | 13G/A | 0% | Feb 20, 2024 | 2y |
| Edward S. Glazer Irrevocable Exempt Trust | MANU Manchester United plc | 13D/A | 15.9% | Feb 20, 2024 | 2y |
| ARCH Venture Fund XII, L.P. | PRME Prime Medicine, Inc. | 13D | 12.9% | Feb 15, 2024 | 2y |
| Kirti Desai | TVGN Tevogen Inc. | 13D | 5.9% | Feb 14, 2024 | 2y |
| James C. Flores | SOC Sable Offshore Corp. | 13D | 25.5% | Feb 14, 2024 | 2y |
| Ryan H. Saadi | TVGN Tevogen Inc. | 13D | 71.9% | Feb 14, 2024 | 2y |
| Davidson Kempner Capital Management LP | TPHS Trinity Place Holdings Inc. | 13D | 40.6% | Feb 14, 2024 | 2y |
| Christopher B. Sarofim | SOC Sable Offshore Corp. | 13D | 11.4% | Feb 14, 2024 | 2y |
| ADAR1 Partners, LP | MACK Merrimack Pharmaceuticals, Inc. | 13G | 6.3% | Feb 13, 2024 | 2y |
| Michael P. Rubin | KYTX Kyverna Therapeutics, Inc. | 13G | 7.6% | Feb 12, 2024 | 2y |
| D. E. Shaw & Co., L.P. | PLCE Childrens Place, Inc. | 13G/A | 7.3% | Feb 12, 2024 | 2y |
| DANIEL TOLHURST | ABTC American Bitcoin Corp. | 13G | 8.53% | Feb 9, 2024 | 2y |